Charles Schwab’s Cellular Biomedicine Group, Inc. CBMG Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q1 | – | Sell |
-28,661
| Closed | -$527K | – | 3542 |
|
|
2020
Q4 | $527K | Hold |
28,661
| – | – | ﹤0.01% | 2974 |
|
|
2020
Q3 | $526K | Sell |
28,661
-1,074
| -4% | -$18.1K | ﹤0.01% | 2864 |
|
|
2020
Q2 | $446K | Buy |
29,735
+1,209
| +4% | +$17.3K | ﹤0.01% | 2883 |
|
|
2020
Q1 | $452K | Hold |
28,526
| – | – | ﹤0.01% | 2749 |
|
|
2019
Q4 | $464K | Hold |
28,526
| – | – | ﹤0.01% | 2846 |
|
|
2019
Q3 | $424K | Hold |
28,526
| – | – | ﹤0.01% | 2868 |
|
|
2019
Q2 | $472K | Buy |
28,526
+3,323
| +13% | +$54.3K | ﹤0.01% | 2838 |
|
|
2019
Q1 | $437K | Buy |
25,203
+703
| +3% | +$12.8K | ﹤0.01% | 2809 |
|
|
2018
Q4 | $433K | Hold |
24,500
| – | – | ﹤0.01% | 2822 |
|
|
2018
Q3 | $445K | Buy |
24,500
+2,900
| +13% | +$59.5K | ﹤0.01% | 2884 |
|
|
2018
Q2 | $423K | Buy |
+21,600
| New | +$405K | ﹤0.01% | 2852 |
|
|
2017
Q2 | – | Sell |
-22,709
| Closed | -$268K | – | 3167 |
|
|
2017
Q1 | $268K | Hold |
22,709
| – | – | ﹤0.01% | 2857 |
|
|
2016
Q4 | $298K | Hold |
22,709
| – | – | ﹤0.01% | 2853 |
|
|
2016
Q3 | $330K | Hold |
22,709
| – | – | ﹤0.01% | 2754 |
|
|
2016
Q2 | $273K | Buy |
22,709
+8,400
| +59% | +$135K | ﹤0.01% | 2818 |
|
|
2016
Q1 | $267K | Hold |
14,309
| – | – | ﹤0.01% | 2809 |
|
|
2015
Q4 | $308K | Hold |
14,309
| – | – | ﹤0.01% | 2852 |
|
|
2015
Q3 | $243K | Hold |
14,309
| – | – | ﹤0.01% | 2908 |
|
|
2015
Q2 | $537K | Buy |
+14,309
| New | +$462K | ﹤0.01% | 2650 |
|
Charles Schwab's CBMG Position: Q1 2021 in Review
Charles Schwab sold out of Cellular Biomedicine Group, Inc. (CBMG) in Q1 2021, closing a stake of 28,661 shares — an estimated $527K sold.
Charles Schwab first reported a position in CBMG in Q2 2015 and held it in 19 quarters. The position peaked at $537K in Q2 2015. 0 funds tracked by Wall St. Rank hold CBMG as of Q1 2021.
- Charles Schwab reported no remaining Cellular Biomedicine Group, Inc. position as of Q1 2021 after selling out during the quarter.
- Charles Schwab sold 28,661 Cellular Biomedicine Group, Inc. shares in Q1 2021, an estimated $527K.
- Charles Schwab first reported a position in Cellular Biomedicine Group, Inc. in Q2 2015 and held it in 19 quarters.
- Charles Schwab's Cellular Biomedicine Group, Inc. position peaked at $537K in Q2 2015.
- 0 funds tracked by Wall St. Rank held Cellular Biomedicine Group, Inc. as of Q1 2021.
Based on Charles Schwab's 13F filing for Q1 2021, filed 17 May 2021.